A Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

Overview

About this study

The purpose of this study is to determine the effectiveness and tolerability of a novel topical preparation for the treatment of cutaneous lesions of mastocytosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Biopsy proven cutaneous mastocytosis with or without evidence of systemic disease.
  • Male and female patients, 18 to 80 years of age.
  • No UVB treatment of the skin for 6 months prior to study entry.
  • No use of topical or systemic corticosteroids for 1 month prior to study entry.
  • Good general health as confirmed by medical history.
  • Female patients of child-bearing potential with negative urine pregnancy test who agree to use effective methods of birth control or remain abstinent during treatment. Participants must use birth control for the entire study and for at least 1 week after the last application of the study formulation. Acceptable methods of birth control include ongoing hormonal contraception methods, (such as birth control pills, patches, injections, vaginal ring, or implants), barrier methods (such as a condom (for men) or diaphragm used with a spermicide), intrauterine devices, tubal ligation, or abstinence.
  • Patients who are willing and capable of cooperating to the extent and degree required by the protocol.
  • Patients who read and sign an approved informed consent for this study.

Exclusion Criteria:

  • Vulnerable study population.
  • Exposure to ultraviolet B (UVB) radiation to any region of the skin surface for 6 months.
  • Regular use of skin lightening agents within 1 month of study entry, including:
    • Topical corticosteroids;
    • Topical bleaching products;
    • Topical retinoids.
  • Use of systemic preparations within 1 month of study entry, including:
    • Systemic corticosteroids;
    • Systemic cyclosporine, interferon;
    • Systemic acitretin, etretinate, isoretinoin;
    • Systemic methotrexate;
    • Systemic photoallergic, phototoxic and/or photosensitizing drugs.
  • UV light therapy and sunbathing.
  • Inability to communicate or cooperate with the Principal Investigator and/or Investigators due to language problems, poor mental development or impaired cerebral function.
  • Pregnant or nursing women.
  • Women planning a pregnancy within the study period.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joseph Butterfield, M.D.

Open for enrollment

Contact information:

Joseph Butterfield M.D.

(507) 284-3783

butterfield.joseph@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20512858

Mayo Clinic Footer